To confirm the efficacy and safety of a single intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with CLTI Rutherford Category 5 and DM.
ID
Source
Brief title
Condition
- Vascular disorders NEC
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Change in Rutherford classification from CLTI Category 5 to Category 4 or lower
12 months after administration of REX-001 or placebo. Success is defined as
complete healing of all ischemic ulcers on the index leg.
Secondary outcome
The following secondary endpoints at 12 months after administration of REX-001
or placebo are defined:
• Change in Rutherford classification from CLI Category 5 to Category 3 or
lower.
• Change from Baseline to Visit 9 (12 months) in TcpO2
• Partial healing of ischemic ulcers ((>= 50% reduction in size as compared to
ulcer size at baseline).
• AFS.
Background summary
CLTI also referred to as limb threat, is an advanced stage of peripheral artery
disease. It includes ischemic rest pain, arterial insufficiency, ulcers and
gangrene. The latter two conditions are jointly referred to as tissue loss,
reflecting the development of surface damage to the limb tissue due to the most
severe stage of ischemia.
CLTI was conceived to identify patients at high-risk for major amputation, but
the increasing prevalence of diabetes mellitus has led to a broader conception
of limb threat that includes the risk of amputation associated with severely
infected and non-healing wounds
The primary objective of the trial is to show that treatment with REX-001 is
superior to treatment with placebo by the change in Rutherford classification
12 months after administration.
Study objective
To confirm the efficacy and safety of a single intra-arterial administration of
REX-001 to treat ischemic ulcers in subjects with CLTI Rutherford Category 5
and DM.
Study design
This trial is a pivotal, placebo-controlled, double-blind, parallel-group,
adaptive trial conducted in subjects with CLTI Rutherford Category 5 and DM.
Minimization will be used to assign eligible subjects in a 2:1 ratio to receive
a single intra-arterial administration of REX-001 or matching placebo into the
index limb.
Trial subjects will be assessed at the screening visit, the BM collection
visit, the baseline visit and at months 1, 2, 3, 6, 9, 12, 18, and 24 after
administration of REX-001or placebo. The primary endpoint for this trial will
be assessed at 12 months.
Intervention
REX-001 is an autologous cell suspension for infusion, administered through an
intra-arterial catheter. The subject will receive one batch of REX-001 at a
target dose of 1 × 109 WBCs (range: 5 × 108 to 1 × 109 autologous WBCs) in a
volume of 20 mL.
For the control group, placebo will be prepared. Placebo will be matched for
colour and volume and its composition is tested to confirm absence of
detectable levels of WBCs.
Target limb arteries are selectively cannulated through a transfemoral approach
with an over the-wire catheter balloon that is positioned in the target artery
of the index leg ( in general the popliteal artery). At this point, the balloon
will be inflated to block blood flow and REX-001 or placebo will be slowly
infused. After administration, the balloon will be deflated and antegrade blood
flow restored.
All subjects will undergo a bone marrow (BM) collection (Visit 2). Under
general or local anesthesia and sedation approximately 250 mL BM is harvested
from the iliac crest. All trial subjects will be administered REX-001 or
placebo unless the yield of the BM collection is insufficient (e.g it is not
possible to manufacture REX-001 at the required dose, between 5 × 108 - 1 × 109
WBCs, or the final product does not meet the release specifications). In these
situations, subjects will be discontinued from the trial. If REX-001 cannot be
manufactured at the required dose, the Sponsor will discuss with the
Investigator whether the subject can be treated with the lower dose, but
outside of the trial.
The subjects assigned to the placebo group may be offered the possibility to
receive REX-001 after the 12 month follow-u p visit has been completed for all
subjects, and if this approach is approved by the national Competent
Authorities. If, at that time, the index leg can no longer be treated, the
treating physician can propose to treat the contralateral leg. For these
subjects, REX-001 will be frozen and stored at an external facility in Spain or
in Germany, depending on where the product was manufactured.
Study burden and risks
During patient participation various examinations and tests will be done. Many
of these tests (associated with burden and risks) are performed to monitor
patient health and well-being and evaluate REX-001 safety and Efficacy
Physical examination: Some examinations/tests can make the patient
uncomfortable.
Vital signs, blood pressure, heart rates are measured.
Blood Draws: patients will have blood drawn at multiple times during the study.
There may be some pain or bruising at the site where patients are pricked.
Pregnancy: In the event that patients become(s) pregnant during the study, the
sponsor will be informed about pregnancy and outcome delivery and health of the
new born.It is not known if REX-001 causes any damage to unborn children.
Therefore, female patients participating in the study must not be pregnant or
be breastfeeding. It is important for patient to understand that contraception
must be used while participating in this study.
Questionnaire: some questions may feel too personal or make the patient
uncomfortable.
General risks associated with participation. There is a very small chance of
allergic reactions. These types of reactions can start shortly after taking the
medication and may appear in the form of itching and redness or difficulty
breathing and may be severe in some cases.
Angiography: patients will be exposed to a small amount of radiation to
visualize the arteries in their leg.
6-minute walking test will be performed to assess how far the subject can walk
and at what time he start to feel pain in legs.
The measurement of oxygen levels of the tissue below the skin on subjects legs
as well the number and size of subject ulcers can make the patient
uncomfortable.
Bone marrow collection will be performed in the hospital and requires
hospitalization overnight.
Pont Street 45
London SW1X 0BD
GB
Pont Street 45
London SW1X 0BD
GB
Listed location countries
Age
Inclusion criteria
1. Aged >= 18 to <= 85 years.
2. Diagnosis of Type I or II DM, established more than one year ago.
3. Glycosylated hemoglobin (HbA1c) < 9%.
4. Subjects with poor or no (surgical or endovascular) revascularization option
classified as CLTI Rutherford Category 5.
The blood circulation in these patients must be compromised at screening, can
be defined as:
• Ankle systolic pressure < 70 mmHg, or
• Toe systolic pressure < 50 mmHg, or
• TcpO2 < 30 mmHg (lying down).
Subjects with non-compressible vessels must qualify on toe pressure or tcpO2.
Poor or no revascularization option means that, in the opinion of the
Investigator, revascularization using surgical or endovascular methods is not
feasible due to unsuitable anatomy of existing vessels, existing comorbidity
and/or previously failed surgical or endovascular revascularization.
*IMPORTANT: All three measurements must be performed and only one may be used
to meet this criteria
Exclusion criteria
1. Advanced CLTI defined as presence of major tissue loss (i.e significant
ulceration and/or gangrene) proximal to the metatarsal heads (CLTI Rutherford
Category 6). Significant ulceration/gangrene means any ulceration that extends
beyond the subcutaneous tissue layer, or any gangrene or tissue necrosis
proximal to the metatarsal heads.
2. CLTI Rutherford Category 4.
3. Uncontrolled or untreated proliferative retinopathy.
4. Failed surgical or endovascular revascularization on the index leg within 10
days prior to screening.
5. Subjects in whom arterial insufficiency in the lower extremity is the result
of acute limb ischemia or an immunological or inflammatory or
non-atherosclerotic disorder (e.g., thromboangiitis obliterans (Buerger*s
Disease), or systemic sclerosis (both limited and diffuse forms).
6. Clinical evidence of invasive infection on index leg defined as major tissue
loss at the mid-foot or heel involving tendon and/or bone, and/or when
according to the Investigator intravenous antibiotics are required to treat the
infection.
7. At screening, the presence of only neuropathic ulcers on the index leg.
8. Amputation at or above the talus on the index leg.
9. Planned major amputation within the first month after randomization.
10. Subjects who may not be healthy enough to successfully complete all
protocol requirements including BM collection, or who are not expected to
survive more than 12 months, or in whom results may be particularly difficult
to assess, as assessed by the Investigator.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| EudraCT | EUCTR2016-003980-21-NL |
| ClinicalTrials.gov | NCT03174522 |
| CCMO | NL60060.000.16 |